Presence of AML was verified by evaluation of liver and spleen morphology (Supplementary Figure 2A), blood count (Supplementary Figure 2B), determining the amount of GFP+ and c-Kit+ cells (Supplementary Figure 2C), and by differentiating myeloid cells using CD11b-Gr-1 flow cytometry (Supplementary Figure 2D). Here, KIT is linked to acute myeloid leukemia.